Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of Leritrelvir With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin in Healthy Participants

NCT06031454 is registered in ClinicalTrials.gov with Guangdong Raynovent Biotech Co., Ltd as lead sponsor.

NCT NCT06031454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06031454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of Leritrelvir With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin in Healthy Participants
Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2023
Completion date
December 31, 2023
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug drug interaction